Brief: Tetra Bio-Pharma announces positive preclinical results of ARDS-003, used for sepsis and viral infections
10/08/2022 11:32
Aug 10 (Reuters) - Tetra Bio Pharma Inc TBP.TO :
* TETRA BIO-PHARMA ANNOUNCES POSITIVE PRECLINICAL RESULTS OF
ARDS-003, A NOVEL THERAPEUTIC FOR SEPSIS AND VIRAL INFECTIONS
* TETRA BIO PHARMA INC - ARDS-003 MAY OFFER STEROID-SPARING
OPPORTUNITIES.
* TETRA BIO PHARMA INC - ARDS-003 HAS DEMONSTRATED ANTIVIRAL
PROPERTIES.
* TETRA BIO PHARMA INC - ARDS-003 DEVELOPED AS AN ORAL
FORMULATION
FOR AN IMMEDIATE RELEASE ADMINISTRATION.
Source text for Eikon: ID:nCNWdgjVya
Further company coverage: TBP.TO
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding